Dyne Therapeutics, Inc. - 10-Q Filing
Dyne Therapeutics filed its quarterly report for the period ended March 31, 2026. The filing includes financial data related to marketable securities (including U.S. Treasury and corporate debt), cash equivalents, loan agreements with Hercules Capital, stock-based compensation plans, and research and development expenses.
Tickers: $DYN